NDA 216675 · Bausch and Lomb INC
Miebo
Perfluorohexyloctane · Ophthalmic · Semifluorinated Alkane
NovelCDER novel approval, May 18, 2023: To treat signs and symptoms of dry eye disease
Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 18, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
15
4 Phase 3, 0 recruiting
FAERS reports
2,325
761 serious, 166 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 10, 2026.
MIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for treatment of the signs and symptoms of dry eye disease. ( 1 )
Mechanism: Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is not known.
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- MIEBO · PERFLUOROHEXYLOCTANE 1.338GM/ML · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Perfluorohexyloctane" as an intervention, any sponsor and status, largest first.
- Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)Pivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT04567329 · 620 participants · Start Nov 18, 2020 · Primary completion Aug 30, 2021
Drug: NOV03; Saline Solution · For: Dry Eye Disease
Sites: Phoenix, Arizona; Garden Grove, California; Hemet, California · 35 sites in all
- Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)Pivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT04139798 · 599 participants · Start Jul 20, 2020 · Primary completion Mar 12, 2021
Drug: NOV03; Placebo · For: Dry Eye Disease (DED)
Sites: Birmingham, Alabama; Scottsdale, Arizona; Glendale, California · 29 sites in all
- A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseasePivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT07128628 · 443 participants · Start Oct 24, 2025 · Primary completion May 28, 2026
Drug: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination; Lifitegrast and 4 more · For: Dry Eye Disease
Sites: Phoenix, Arizona; Glendale, California; Long Beach, California · 32 sites in all
- Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)Pivotal-lookingCompleted
Novaliq GmbHIndustry
NCT03333057 · 336 participants · Start Jan 3, 2018 · Primary completion May 18, 2018
Drug: NOV03; Placebo · For: Dry Eye Disease (DED)
Sites: Artesia, California; Newport Beach, California; Santa Ana, California · 11 sites in all
- SYSTANE® PRO vs. MIEBO™ in Dry Eye DiseasePivotal-lookingCompleted
Indiana UniversityAcademic, hospital or other
NCT07243275 · 269 participants · Start Feb 18, 2026 · Primary completion Jul 28, 2026
Drug: SYSTANE® PRO; MIEBO™ (Perfluorohexyloctane, PFHO) · For: Dry Eye Disease (DED)
Sites: Newport Beach, California; Bloomington, Indiana; Pittsburg, Kansas · 4 sites in all
- Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)Pivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT04140227 · 256 participants · Start Sep 24, 2020 · Primary completion Jan 5, 2022
Drug: NOV03 · For: Dry Eye Disease (DED)
Sites: Birmingham, Alabama; Scottsdale, Arizona; Glendale, California · 28 sites in all
- A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.Pivotal-lookingActive, not recruiting
Bausch & Lomb IncorporatedIndustry
NCT06565650 · 216 participants · Start Jul 31, 2024 · Primary completion Nov 2025
Drug: Miebo; Saline · For: Dry Eye
Sites: Glendale, California; Murrieta, California; Newport Beach, California · 12 sites in all
- Perfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry EyePivotal-lookingNot yet recruiting
Beijing Tongren HospitalAcademic, hospital or other
NCT07679685 · 159 participants (planned) · Start Jun 30, 2026 · Primary completion Feb 28, 2027
Drug: 0.1% Sodium Hyaluronate Eye Drops; Perfluorohexyloctane Eye Drops (PFHO) · For: Dry Eye
Sites: Beijing, China; Guangzhou, China; Shanghai, China · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- inappropriate schedule of product administration328
- eye pain307
- eye irritation297
- vision blurred275
- product use issue240
- product delivery mechanism issue201
- drug ineffective177
- circumstance or information capable of leading to medication error170
- product use complaint164
- ocular hyperaemia159
- death158
- dry eye154
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 10 |
| 2023 | 66 |
| 2024 | 398 |
| 2025 | 926 |
| 2026 | 922 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Miebo (Perfluorohexyloctane/PF)
2024 spending
$116M
Beneficiaries
48,590
134,845 claims
Per beneficiary
$2,394
$246.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $9,327,677 |
| 2024 | $116,305,942 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical pharmacologic treatments for dry eye disease: A systematic review.
Tong L, Liu Z, Şahin A, et al. · Ocul Surf 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.
Tauber J, Berdy GJ, Wirta DL, et al. · Ophthalmology 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy of Perfluorohexyloctane for the Treatment of Patients with Dry Eye Disease: A Meta-Analysis.
Taloni A, Coco G, Pellegrini M, et al. · Ophthalmic Res 2025 · Meta-Analysis, Systematic Review
- Our experience with perfluorohexyloctane (F6H8) as a temporary endotamponade in vitreoretinal surgery.
Stefaniotou MI, Aspiotis MV, Kitsos GD, et al. · Eur J Ophthalmol 2002 · Clinical Trial
- Efficacy and safety of perfluorohexyloctane (PFHO) in patients with dry eye disease (DED) due to meibomian gland dysfunction (MGD): Systematic review and meta-analysis.
Munsab R, Zafar R, Fatima A, et al. · Medicine (Baltimore) 2025 · Meta-Analysis, Systematic Review
- Factors Associated With Perfluorohexyloctane Treatment Response in Dry Eye Disease Associated With Meibomian Gland Dysfunction.
Gu H, Li Z, Zhu L · Cornea 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Bausch and Lomb INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.